2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Neurotrophic or Neurotoxic Disease

Neurotrophic or Neurotoxic Disease

Central nervous system toxicity from local anesthetics is a biphasic process characterized initially by excitatory effects, including perioral numbness, visual disturbances, and lowered seizure threshold, progressing to depression with drowsiness, unconsciousness, and potentially coma or cardiac arrest. This toxicity is influenced by the drug's lipid solubility and protein-binding capacity, with symptoms arising from disruption of inhibitory neuronal activity. Early signs such as paresthesia and visual changes warrant immediate cessation of the procedure and preparation for potential seizures, managed with 100% oxygen, benzodiazepines, and airway support. Cardiac toxicity typically occurs at higher systemic concentrations and is particularly concerning with bupivacaine due to its high affinity for Purkinje fibers, leading to refractory arrhythmias like ventricular fibrillation, necessitating strict avoidance of intravascular injection. Neurotrophic factors are essential for neuronal growth, survival, and differentiation, supporting neural network formation and embryonic development, though they are not directly related to anesthetic toxicity.

 

Neurotrophic or Neurotoxic Disease (3):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-182568
    Iocarmic acid 10397-75-8
    Iocarmic acid is a myelographic contrast agent. Iocarmic acid is used for lumbar nerve root angiography and ventriculography. Iocarmic acid induces arachnoiditis via lumbar subarachnoid injection. Iocarmic acid can be used for the research of arachnoiditis.
    Iocarmic acid
  • HY-182010
    nAChR antagonist 3 3114746-65-2
    nAChR antagonist 3 is a selective α7 nAChR antagonist with an IC50 of 0.86 μM. nAChR antagonist 3 exerts a protective effect against paraoxon-induced toxicity. nAChR antagonist 3 can be used for the research of organophosphate poisoning.
    nAChR antagonist 3
  • HY-106901B
    Asoxime dimesylate 144252-71-1
    Asoxime dimesylate (HI-6 dimesylate) is an orally active thiosemicarbazone-based antidote. Asoxime dimesylate is a reversible inhibitor of AChE, and its core mechanism of action is to re-activate AChE inhibited by nerve toxins, thereby restoring the cholinergic nerve function. Asoxime dimesylate significantly restores the function of poisoned muscles without reactivating AChE. Asoxime dimesylate is an antagonist of acetylcholine receptors (AChRs), including nicotinic receptor and α7 nAChR. Asoxime dimesylate can serve as an effective immunomodulator, improving the immune effect of the nervous system.
    Asoxime dimesylate